Display options
Cite
Brilhante-da-Silva N, de Oliveira Sousa RM, Arruda A, et al. Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms. Mol Diagn Ther. 2021;25(4):439-456doi: 10.1007/s40291-021-00533-7.
Brilhante-da-Silva, N., de Oliveira Sousa, R. M., Arruda, A., Dos Santos, E. L., Marinho, A. C. M., Stabeli, R. G., Fernandes, C. F. C., & Pereira, S. D. S. (2021). Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms. Molecular diagnosis & therapy, 25(4), 439-456. https://doi.org/10.1007/s40291-021-00533-7
Brilhante-da-Silva, Nairo, et al. "Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms." Molecular diagnosis & therapy vol. 25,4 (2021): 439-456. doi: https://doi.org/10.1007/s40291-021-00533-7
Brilhante-da-Silva N, de Oliveira Sousa RM, Arruda A, Dos Santos EL, Marinho ACM, Stabeli RG, Fernandes CFC, Pereira SDS. Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms. Mol Diagn Ther. 2021 Jul;25(4):439-456. doi: 10.1007/s40291-021-00533-7. Epub 2021 Jun 19. PMID: 34146333.
Copy Download .nbib Format: NLM
Share it on

Mol Diagn Ther. 2021 Jul;25(4):439-456. doi: 10.1007/s40291-021-00533-7. Epub 2021 Jun 19.

Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.

Molecular diagnosis & therapy

Nairo Brilhante-da-Silva, Rosa Maria de Oliveira Sousa, Andrelisse Arruda, Eliza Lima Dos Santos, Anna Carolina Machado Marinho, Rodrigo Guerino Stabeli, Carla Freire Celedonio Fernandes, Soraya Dos Santos Pereira

Affiliations

  1. Laboratório de Engenharia de Anticorpos, Fundação Oswaldo Cruz, Fiocruz, Unidade Rondônia, Porto Velho, RO, 76812-245, Brazil.
  2. Programa de Pós-Graduação em Biologia Celular e Molecular, Instituto Oswaldo Cruz, IOC, Rio de Janeiro, Brazil.
  3. Plataforma de Desenvolvimento de Anticorpos e Nanocorpos, Fundação Oswaldo Cruz, Fiocruz Ceará, Eusebio, Brazil.
  4. Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Ceará, Fortaleza, Brazil.
  5. Plataforma Bi-institucional de Medicina Translacional.Fundação Oswaldo Cruz-USP, Ribeirão Preto, São Paulo, Brazil.
  6. Laboratório de Engenharia de Anticorpos, Fundação Oswaldo Cruz, Fiocruz, Unidade Rondônia, Porto Velho, RO, 76812-245, Brazil. [email protected].
  7. Programa de Pós-Graduação em Biologia Celular e Molecular, Instituto Oswaldo Cruz, IOC, Rio de Janeiro, Brazil. [email protected].
  8. Programa de Pós-graduação em Biologia Experimental, Universidade Federal de Rondônia, Porto Velho, Brazil. [email protected].

PMID: 34146333 DOI: 10.1007/s40291-021-00533-7

Abstract

The distinct biophysical and pharmaceutical properties of camelid single-domain antibodies, referred to as VHHs or nanobodies, are associated with their nanometric dimensions, elevated stability, and antigen recognition capacity. These biomolecules can circumvent a number of diagnostic system limitations, especially those related to the size and stability of conventional immunoglobulins currently used in enzyme-linked immunosorbent assays and point-of-care, electrochemical, and imaging assays. In these formats, VHHs are directionally conjugated to different molecules, such as metallic nanoparticles, small peptides, and radioisotopes, which demonstrates their comprehensive versatility. Thus, the application of VHHs in diagnostic systems range from the identification of cancer cells to the detection of degenerative disease biomarkers, viral antigens, bacterial toxins, and insecticides. The improvements of sensitivity and specificity are among the central benefits resulting from the use of VHHs, which are indispensable parameters for high-quality diagnostics. Therefore, this review highlights the main biotechnological advances related to camelid single-domain antibodies and their use in in vitro and in vivo diagnostic approaches for human health.

References

  1. Williams KL, Stumpf M, Naiman NE, Ding S, Garrett M, Gobillot T, et al. Identification of HIV gp41-specific antibodies that mediate killing of infected cells. PLOS Pathog. 2019;15(2):e1007572. - PubMed
  2. Wenzel EV, Bosnak M, Tierney R, Schubert M, Brown J, Dübel S, et al. Human antibodies neutralizing diphtheria toxin in vitro and in vivo. Sci Rep. 2020;10:1–21. - PubMed
  3. Schneider DW, Heitner T, Alicke B, Light DR, McLean K, Satozawa N, et al. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med. 2009;50:435–43. - PubMed
  4. Dominik PK, Borowska MT, Dalmas O, Kim SS, Perozo E, Keenan RJ, et al. Conformational chaperones for structural studies of membrane proteins using antibody phage display with nanodiscs. Structure. 2016;24:300–9. - PubMed
  5. Buser DP, Schleicher KD, Prescianotto-Baschong C, Spiess M. A versatile nanobody-based toolkit to analyze retrograde transport from the cell surface. Proc Natl Acad Sci U S A. 2018;115:E6227–36. - PubMed
  6. Zimmermann I, Egloff P, Hutter CAJ, Arnold FM, Stohler P, Bocquet N, et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. Elife. 2018;3:1–32. - PubMed
  7. Ren X, Yan J, Wu D, Wei Q, Wan Y. Nanobody-based apolipoprotein E immunosensor for point-of-care testing. ACS Sensors. 2017;2:1267–71. - PubMed
  8. Sroga P, Safronetz D, Stein DR. Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases. Future Virol. 2020;15:fvl-2019-0167. - PubMed
  9. Gasser M, Waaga-Gasser AM. Therapeutic antibodies in cancer therapy. Adv Exp Med Biol. 2016;917:95–120. - PubMed
  10. Prado NDR, Pereira SS, da Silva MP, Morais MSS, Kayano AM, Moreira-Dill LS, et al. Inhibition of the myotoxicity induced by Bothrops jararacussu venom and isolated phospholipases A2 by specific camelid single-domain antibody fragments. PLoS One. 2016;11:e0151363. - PubMed
  11. Luiz MB, Pereira SS, Prado NDR, Gonçalves NR, Kayano AM, Moreira-Dill LS, et al. Camelid single-domain antibodies (VHHs) against crotoxin: a basis for developing modular building blocks for the enhancement of treatment or diagnosis of crotalic envenoming. Toxins (Basel). 2018;10:142. - PubMed
  12. Haraya K, Tachibana T, Igawa T. Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. Drug Metab Pharmacokinet. 2019;34:25–41. - PubMed
  13. Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34:11–26. - PubMed
  14. Chiu ML, Gilliland GL. Engineering antibody therapeutics. Curr Opin Struct Biol. 2016;38:163–73. - PubMed
  15. Fu R, Carroll L, Yahioglu G, Aboagye EO, Miller PW. Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications. ChemMedChem. 2018;13:2466–78. - PubMed
  16. Lee CH, Lee YC, Lee YL, Leu SJ, Lin LT, Chen CC, et al. Single chain antibody fragment against venom from the snake Daboia russelii formosensis. Toxins (Basel). 2017;9:347. - PubMed
  17. Pan X, Zhou P, Fan T, Wu Y, Zhang J, Shi X, et al. Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro. Antiviral Res. 2020;182:104868. - PubMed
  18. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126–36. - PubMed
  19. Schroeder HWJ, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125:S41-52. - PubMed
  20. Abbas AK, Lichtman AH, Pillai S. Livro: Imunologia Celular e Molecular. In: Abbas AK, Pillai S, Lichtman AH editors. Livros de medicina. 8th ed. Elsevier; 2015. - PubMed
  21. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97. - PubMed
  22. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–8. - PubMed
  23. Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LGJ, de Geus B. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol. 2000;37:579–90. - PubMed
  24. Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. Comparison of llama V(H) sequences from conventional and heavy chain antibodies. Mol Immunol. 1997;34:1121–31. - PubMed
  25. Siontorou CG. Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomed. 2013;8:4215–27. - PubMed
  26. Arbabi-Ghahroudi M. Camelid single-domain antibodies: historical perspective and future outlook. Front Immunol. 2017;8:1–8. - PubMed
  27. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006;103:4586–91. - PubMed
  28. Henry KA, MacKenzie CR. Antigen recognition by single-domain antibodies: structural latitudes and constraints. MAbs. 2018;10:815–26. - PubMed
  29. Muyldermans S, Lauwereys M. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J Mol Recognit. 1999;12:131–40. - PubMed
  30. Kolkman JA, Law DA. Nanobodies: from llamas to therapeutic proteins. Drug Discov Today Technol. 2010;7:e139–46. - PubMed
  31. Legler PM, Compton JR, Hale ML, Anderson GP, Olson MA, Millard CB, et al. Stability of isolated antibody-antigen complexes as a predictive tool for selecting toxin neutralizing antibodies. MAbs. 2017;9:43–57. - PubMed
  32. Liu JL, Goldman ER, Zabetakis D, Walper SA, Turner KB, Shriver-Lake LC, et al. Enhanced production of a single domain antibody with an engineered stabilizing extra disulfide bond. Microb Cell Fact. 2015;14:158. - PubMed
  33. Turner KB, Zabetakis D, Goldman ER, Anderson GP. Enhanced stabilization of a stable single domain antibody for SEB toxin by random mutagenesis and stringent selection. Protein Eng Des Sel. 2014;27:89–95. - PubMed
  34. Turner KB, Liu JL, Zabetakis D, Lee AB, Anderson GP, Goldman ER. Improving the biophysical properties of anti-ricin single-domain antibodies. Biotechnol Rep. 2015;6:27–35. - PubMed
  35. Walper SA, Battle SR, Audrey Brozozog Lee P, Zabetakis D, Turner KB, Buckley PE, et al. Thermostable single domain antibody-maltose binding protein fusion for Bacillus anthracis spore protein BclA detection. Anal Biochem. 2014;447:64–73. - PubMed
  36. Goldman ER, Liu JL, Zabetakis D, Anderson GP. Enhancing stability of camelid and shark single domain antibodies: an overview. Front Immunol. 2017;8:1–11. - PubMed
  37. Pereira SS, Moreira-Dill LS, Morais MSS, Prado NDR, Barros ML, Koishi AC, et al. Novel camelid antibody fragments targeting recombinant nucleoprotein of Araucaria hantavirus: a prototype for an early diagnosis of hantavirus pulmonary syndrome. PLoS One. 2014;9:e108067. - PubMed
  38. Liu CC, Yu JS, Wang PJ, Hsiao YC, Liu CH, Chen YC, et al. Development of sandwich ELISA and lateral flow strip assays for diagnosing clinically significant snakebite in Taiwan. PLoS Negl Trop Dis. 2018;12:1–23. - PubMed
  39. Chen Q, Zhou Y, Yu J, Liu W, Li F, Xian M, et al. An efficient constitutive expression system for anti-CEACAM5 nanobody production in the yeast Pichia pastoris. Protein Expr Purif. 2019;155:43–7. - PubMed
  40. Gómez-Sebastián S, Nuñez MC, Garaicoechea L, Alvarado C, Mozgovoj M, Lasa R, et al. Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo. BMC Biotechnol. 2012;12:59. - PubMed
  41. Ashour J, Schmidt FI, Hanke L, Cragnolini J, Cavallari M, Altenburg A, et al. Intracellular expression of camelid single-domain antibodies specific for influenza virus nucleoprotein uncovers distinct features of its nuclear localization. J Virol. 2015;89:2792–800. - PubMed
  42. Saberianfar R, Chin-Fatt A, Scott A, Henry KA, Topp E, Menassa R. Plant-produced chimeric VHH-sIgA against enterohemorrhagic E. coli intimin shows cross-serotype inhibition of bacterial adhesion to epithelial cells. Front Plant Sci. 2019;10:270. - PubMed
  43. Nguyen-Duc T, Peeters E, Muyldermans S, Charlier D, Hassanzadeh-Ghassabeh G. Nanobody - PubMed
  44. Pardon E, Laeremans T, Triest S, Rasmussen SGF, Wohlkönig A, Ruf A, et al. A general protocol for the generation of nanobodies for structural biology. Nat Protoc. 2014;9:674–93. - PubMed
  45. Götzke H, Kilisch M, Martínez-Carranza M, Sograte-Idrissi S, Rajavel A, Schlichthaerle T, et al. The ALFA-tag is a highly versatile tool for nanobody-based bioscience applications. Nat Commun. 2019;10:4403. - PubMed
  46. Vrentas CE, Moayeri M, Keefer AB, Greaney AJ, Tremblay J, O’Mard D, et al. A diverse set of single-domain antibodies (VHHs) against the anthrax toxin lethal and edema factors provides a basis for construction of a bispecific agent that protects against anthrax infection. J Biol Chem. 2016;291:21596–606. - PubMed
  47. Fernandes CFC, Pereira S dos S, Luiz MB, Zuliani JP, Furtado GP, Stabeli RG. Camelid single-domain antibodies as an alternative to overcome challenges related to the prevention, detection, and control of neglected tropical diseases. Front Immunol. 2017;8:1–8. - PubMed
  48. Bailon Calderon H, Yaniro Coronel VO, Cáceres Rey OA, Colque Alave EG, Leiva Duran WJ, Padilla Rojas C, et al. Development of nanobodies against hemorrhagic and myotoxic components of Bothrops atrox snake venom. Front Immunol. 2020;11:1–12. - PubMed
  49. Huo J, Le Bas A, Ruza RR, Duyvesteyn HME, Mikolajek H, Malinauskas T, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27:846–54. - PubMed
  50. Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell. 2020;181:1004–15.e15. - PubMed
  51. Abu Alshamat E, Kweider M, Abbady AQ. Camel nanobodies: promising molecular tools against leishmaniasis. Parasite Immunol. 2020;42(9):e12718. - PubMed
  52. Qiu Y Lou, He QH, Xu Y, Bhunia AK, Tu Z, Chen B, et al. Deoxynivalenol-mimic nanobody isolated from a naïve phage display nanobody library and its application in immunoassay. Anal Chim Acta. 2015;887:201–8. - PubMed
  53. Harmsen MM, Seago J, Perez E, Charleston B, Eblé PL, Dekker A. Isolation of single-domain antibody fragments that preferentially detect intact (146s) particles of foot-and-mouth disease virus for use in vaccine quality control. Front Immunol. 2017;8:960. - PubMed
  54. Doerflinger SY, Tabatabai J, Schnitzler P, Farah C, Rameil S, Sander P, et al. Development of a nanobody-based lateral flow immunoassay for detection of human norovirus. mSphere. 2016;1:1–6. - PubMed
  55. Pinto-Torres JE, Goossens J, Ding J, Li Z, Lu S, Vertommen D, et al. Development of a nanobody-based lateral flow assay to detect active Trypanosoma congolense infections. Sci Rep. 2018;8:1–15. - PubMed
  56. Morales-Yánez F, Trashin S, Hermy M, Sariego I, Polman K, Muyldermans S, et al. Fast one-step ultrasensitive detection of Toxocara canis antigens by a nanobody-based electrochemical magnetosensor. Anal Chem. 2019;91:11582–8. - PubMed
  57. Khaleghi S, Rahbarizadeh F, Ahmadvand D, Hosseini HRM. Anti-HER2 VHH targeted magnetoliposome for intelligent magnetic resonance imaging of breast cancer cells. Cell Mol Bioeng. 2017;10:263–72. - PubMed
  58. Ramos-Gomes F, Bode J, Sukhanova A, Bozrova SV, Saccomano M, Mitkovski M, et al. Single- and two-photon imaging of human micrometastases and disseminated tumour cells with conjugates of nanobodies and quantum dots. Sci Rep. 2018;8:1–12. - PubMed
  59. Chen Y-J, Chen M, Hsieh Y-C, Su Y-C, Wang C-H, Cheng C-M, et al. Development of a highly sensitive enzyme-linked immunosorbent assay (ELISA) through use of poly-protein G-expressing cell-based microplates. Sci Rep. 2018;8:17868. - PubMed
  60. Zhou D, Pei C, Yang K, Ye J, Wan S, Li Q, et al. Development and application of a monoclonal-antibody-based blocking ELISA for detection of Japanese encephalitis virus NS1 antibodies in swine. Arch Virol. 2019;164:1535–42. - PubMed
  61. Lakshmipriya T, Gopinath SCB, Hashim U, Tang TH. Signal enhancement in ELISA: biotin-streptavidin technology against gold nanoparticles. J Taibah Univ Med Sci. 2016;11:432–8. - PubMed
  62. Ducancel F, Muller BH. Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs. 2012;4:445–57. - PubMed
  63. Abeijon C, Dilo J, Tremblay JM, Viana AG, Bueno LL, Carvalho SFG, et al. Use of VHH antibodies for the development of antigen detection test for visceral leishmaniasis. Parasite Immunol. 2018;40:1–10. - PubMed
  64. Harmsen MM, Fijten HPD. Improved functional immobilization of llama single-domain antibody fragments to polystyrene surfaces using small peptides. J Immunoass Immunochem. 2012;33:234–51. - PubMed
  65. Shriver-Lake LC, Goldman ER, Dean SN, Liu JL, Davis TM, Anderson GP. Lipid-tagged single domain antibodies for improved enzyme-linked immunosorbent assays. J Immunol Methods. 2020;481-482:112790. - PubMed
  66. Li M, Zhu M, Zhang C, Liu X, Wan Y. Uniform orientation of biotinylated nanobody as an affinity binder for detection of Bacillus thuringiensis (Bt) Cry1Ac toxin. Toxins (Basel). 2014;6:3208–22. - PubMed
  67. Zhu M, Gong X, Hu Y, Ou W, Wan Y. Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1. J Transl Med. 2014;12:1–10. - PubMed
  68. Kumada Y, Kang B, Yamakawa K, Kishimoto M, Horiuchi JI. Efficient preparation and site-directed immobilization of VHH antibodies by genetic fusion of poly(methylmethacrylate)-binding peptide (PMMA-Tag). Biotechnol Prog. 2015;31:1563–70. - PubMed
  69. Ma Z, Wang T, Li Z, Guo X, Tian Y, Li Y, et al. A novel biotinylated nanobody-based blocking ELISA for the rapid and sensitive clinical detection of porcine epidemic diarrhea virus. J Nanobiotechnol. 2019;17:96. - PubMed
  70. Wang Y, Li P, Majkova Z, Bever CRS, Kim HJ, Zhang Q, et al. Isolation of alpaca anti-idiotypic heavy-chain single-domain antibody for the aflatoxin immunoassay. Anal Chem. 2013;85:8298–303. - PubMed
  71. Shu M, Xu Y, Wang D, Liu X, Li Y, He Q, et al. Anti-idiotypic nanobody: a strategy for development of sensitive and green immunoassay for fumonisin B1. Talanta. 2015;143:388–93. - PubMed
  72. Xu Y, Xiong L, Li Y, Xiong Y, Tu Z, Fu J, et al. Anti-idiotypic nanobody as citrinin mimotope from a naive alpaca heavy chain single domain antibody library. Anal Bioanal Chem. 2015;407:5333–41. - PubMed
  73. Zhang C, Zhang Q, Tang X, Zhang W, Li P. Development of an anti-idiotypic VHH antibody and toxin-free enzyme immunoassay for ochratoxin A in cereals. Toxins (Basel). 2019;11:280. - PubMed
  74. Vashist SK, Luong JHT. Point-of-care technologies enabling next-generation healthcare monitoring and management. Springer International Publishing; 2019. - PubMed
  75. Toubanaki DK, Margaroni M, Prapas A, Karagouni E. Development of a nanoparticle-based lateral flow strip biosensor for visual detection of whole nervous necrosis virus particles. Sci Rep. 2020;10:1–12. - PubMed
  76. Tomás AL, de Almeida MP, Cardoso F, Pinto M, Pereira E, Franco R, et al. Development of a gold nanoparticle-based lateral-flow immunoassay for pneumocystis pneumonia serological diagnosis at point-of-care. Front Microbiol. 2019;10:2917. - PubMed
  77. Anfossi L, Di Nardo F, Profiti M, Nogarol C, Cavalera S, Baggiani C, et al. A versatile and sensitive lateral flow immunoassay for the rapid diagnosis of visceral leishmaniasis. Anal Bioanal Chem. 2018;410:4123–34. - PubMed
  78. Wang J, Yiu B, Obermeyer J, Filipe CDM, Brennan JD, Pelton R. Effects of temperature and relative humidity on the stability of paper-immobilized antibodies. Biomacromol. 2012;13:559–64. - PubMed
  79. Henderson CA, McLiesh H, Then WL, Garnier G. Activity and longevity of antibody in paper-based blood typing diagnostics. Front Chem. 2018;6:1–7. - PubMed
  80. Goossens J, Sein H, Lu S, Radwanska M, Muyldermans S, Sterckx YGJ, et al. Functionalization of gold nanoparticles with nanobodies through physical adsorption. Anal Methods. 2017;9:3430–40. - PubMed
  81. Loynachan CN, Thomas MR, Gray ER, Richards DA, Kim J, Miller BS, et al. Platinum nanocatalyst amplification: redefining the gold standard for lateral flow immunoassays with ultrabroad dynamic range. ACS Nano. 2018;12:279–88. - PubMed
  82. Koromyslova AD, Hansman GS. Nanobody binding to a conserved epitope promotes norovirus particle disassembly. J Virol. 2015;89:2718–30. - PubMed
  83. Fatima A, Wang H, Kang K, Xia L, Wang Y, Ye W, et al. Development of VHH antibodies against dengue virus type 2 NS1 and comparison with monoclonal antibodies for use in immunological diagnosis. PLoS ONE. 2014;9:1–12. - PubMed
  84. Oliveira JP, Prado AR, Keijok WJ, Antunes PWP, Yapuchura ER, Guimarães MCC. Impact of conjugation strategies for targeting of antibodies in gold nanoparticles for ultrasensitive detection of 17β-estradiol. Sci Rep. 2019;9:1–8. - PubMed
  85. Hattori T, Umetsu M, Nakanishi T, Sawai S, Kikuchi S, Asano R, et al. A high-affinity gold-binding camel antibody: antibody engineering for one-pot functionalization of gold nanoparticles as biointerface molecules. Bioconjug Chem. 2012;23:1934–44. - PubMed
  86. El-Moghazy AY, Huo J, Amaly N, Vasylieva N, Hammock BD, Sun G. An innovative nanobody-based electrochemical immunosensor using decorated nylon nanofibers for point-of-care monitoring of human exposure to pyrethroid insecticides. ACS Appl Mater Interfaces. 2020;12:6159–68. - PubMed
  87. Huang L, Muyldermans S, Saerens D. Nanobodies - PubMed
  88. Li T, Vandesquille M, Koukouli F, Dudeffant C, Youssef I, Lenormand P, et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 2016;243:1–10. - PubMed
  89. Van Audenhove I, Gettemans J. Nanobodies as versatile tools to understand, diagnose, visualize and treat cancer. EBioMedicine. 2016;8:40–8. - PubMed
  90. Jailkhani N, Ingram JR, Rashidian M, Rickelt S, Tian C, Mak H, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci U S A. 2019;116:14181–90. - PubMed
  91. D’Huyvetter M, Aerts A, Xavier C, Vaneycken I, Devoogdt N, Gijs M, et al. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging. 2012;7:254–64. - PubMed
  92. Hu Y, Liu C, Muyldermans S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol. 2017;8:1442. - PubMed
  93. Debie P, Devoogdt N, Hernot S. Targeted nanobody-based molecular tracers for nuclear imaging and image-guided surgery. Antibodies. 2019;8:12. - PubMed
  94. Oliveira Sabrina, Van Dongen GAMS, Stigter-Van Walsum M, Roovers RC, Stam JC, Mali W, et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging. 2012;11:33–46. - PubMed
  95. Romao E, Krasniqi A, Maes L, Vandenbrande C, Sterckx YGJ, Stijlemans B, et al. Identification of nanobodies against the acute. Int J Mol Sci. 2020;21:310. - PubMed
  96. Debie P, Van Quathem J, Hansen I, Bala G, Massa S, Devoogdt N, et al. Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image-guided surgery. Mol Pharm. 2017;14:1145–53. - PubMed
  97. Fan X, Wang L, Guo Y, Tu Z, Li L, Tong H, et al. Ultrasonic nanobubbles carrying anti-PSMA nanobody: construction and application in prostate cancer-targeted imaging. PLoS ONE. 2015;10:1–13. - PubMed
  98. Punjabi M, Xu L, Ochoa-Espinosa A, Kosareva A, Wolff T, Murtaja A, et al. Ultrasound molecular imaging of atherosclerosis with nanobodies. Arterioscler Thromb Vasc Biol. 2019;39:2520–30. - PubMed
  99. Vaneycken I, Govaert J, Vincke C, Caveliers V, Lahoutte T, De Baetselier P, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med. 2010;51:1099–106. - PubMed
  100. Ashton JR, Gottlin EB, Patz EF, West JL, Badea CT. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. PLoS One. 2018;13:e0206950. - PubMed
  101. Senders ML, Hernot S, Carlucci G, van de Voort JC, Fay F, Calcagno C, et al. Nanobody-facilitated multiparametric PET/MRI phenotyping of atherosclerosis. JACC Cardiovasc Imaging. 2019;12:2015–26. - PubMed
  102. Xing Y, Chand G, Liu C, Cook GJR, O’Doherty J, Zhao L, et al. Early phase I study of a 99mTc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer. J Nucl Med. 2019;60:1213–20. - PubMed
  103. Huang L, Gainkam LOT, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008;10:167–75. - PubMed
  104. Gainkam LOT, Keyaerts M, Caveliers V, Devoogdt N, Vanhove C, Van Grunsven L, et al. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol. 2011;13:940–8. - PubMed
  105. Pant K, Neuber C, Zarschler K, Wodtke J, Meister S, Haag R, et al. Active targeting of dendritic polyglycerols for diagnostic cancer imaging. Small. 2020;16: e1905013. - PubMed
  106. Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011;25:2433–46. - PubMed
  107. D’Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, et al. Targeted radionuclide therapy with a 177 Lu-labeled anti-HER2 nanobody. Theranostics. 2014;4:708–20. - PubMed
  108. Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27–33. - PubMed
  109. Li C, Zhang Y, Wang L, Feng H, Xia X, Ma J, et al. A novel multivalent 99m Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts. Nucl Med Biol. 2015;42:547–54. - PubMed
  110. Piramoon M, Hosseinimehr SJ, Omidfar K, Noaparast Z, Abedi SM. 99m Tc-anti-epidermal growth factor receptor nanobody for tumor imaging. Chem Biol Drug Des. 2017;89:498–504. - PubMed
  111. Warnders FJ, Van Scheltinga AGT, Knuehl C, Van Roy M, De Vries EFJ, Kosterink JGW, et al. Human epidermal growth factor receptor 3-specific tumor uptake and biodistribution of 89Zr-MSB0010853 visualized by real-time and noninvasive pet imaging. J Nucl Med. 2017;58:1210–5. - PubMed
  112. Van Elssen CHMJ, Rashidian M, Vrbanac V, Wucherpfennig KW, El Habre Z, Sticht J, et al. Noninvasive imaging of human immune responses in a human xenograft model of graft-versus-host disease. J Nucl Med. 2017;58:1003–8. - PubMed
  113. Broisat A, Hernot S, Toczek J, De Vos J, Riou LM, Martin S, et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res. 2012;110:927–37. - PubMed
  114. Zheng F, Devoogdt N, Sparkes A, Morias Y, Abels C, Stijlemans B, et al. Monitoring liver macrophages using nanobodies targeting Vsig4: concanavalin A induced acute hepatitis as paradigm. Immunobiology. 2015;220:200–9. - PubMed
  115. Zheng F, Sparkes A, De Baetselier P, Schoonooghe S, Stijlemans B, Muyldermans S, et al. Molecular imaging with Kupffer cell-targeting nanobodies for diagnosis and prognosis in mouse models of liver pathogenesis. Mol Imaging Biol. 2017;19:49–58. - PubMed
  116. Zheng F, Put S, Bouwens L, Lahoutte T, Matthys P, Muyldermans S, et al. Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis. J Nucl Med. 2014;55:824–9. - PubMed
  117. Xavier C, Vaneycken I, D’huyvetter M, Heemskerk J, Keyaerts M, Vincke C, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54:776–84. - PubMed
  118. Xavier C, Blykers A, Vaneycken I, D’Huyvetter M, Heemskerk J, Lahoutte T, et al. 18F-nanobody for PET imaging of HER2 overexpressing tumors. Nucl Med Biol. 2016;43:247–52. - PubMed
  119. Balhuizen A, Massa S, Mathijs I, Turatsinze JV, De Vos J, Demine S, et al. A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells. Sci Rep. 2017;7:1–13. - PubMed
  120. Gainkam LOT, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008;49:788–95. - PubMed
  121. Broos K, Keyaerts M, Lecocq Q, Renmans D, Nguyen T, Escors D, et al. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget. 2017;8:41932–46. - PubMed
  122. Broos K, Lecocq Q, Xavier C, Bridoux J, Nguyen TT, Corthals J, et al. Evaluating a single domain antibody targeting human PD-L1 as a nuclear imaging and therapeutic agent. Cancers (Basel). 2019;11:872. - PubMed
  123. Lecocq Q, Zeven K, De Vlaeminck Y, Martens S, Massa S, Goyvaerts C, et al. Noninvasive imaging of the immune checkpoint LAG-3 using nanobodies, from development to pre-clinical use. Biomolecules. 2019;9:548. - PubMed
  124. Lemaire M, D’Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic nanobodies. Leukemia. 2014;28:444–7. - PubMed
  125. Chatalic KLS, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, et al. A novel 111In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT/CT imaging of prostate cancer. J Nucl Med. 2015;56:1094–9. - PubMed
  126. Evazalipour M, D’Huyvetter M, Tehrani BS, Abolhassani M, Omidfar K, Abdoli S, et al. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Contrast Media Mol Imaging. 2014;9:211–20. - PubMed
  127. Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012;72:4165–77. - PubMed
  128. Put S, Schoonooghe S, Devoogdt N, Schurgers E, Avau A, Mitera T, et al. SPECT imaging of joint inflammation with nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med. 2013;54:807–14. - PubMed
  129. Vandesquille M, Li T, Po C, Ganneau C, Lenormand P, Dudeffant C, et al. Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer’s disease. MAbs. 2017;9:1016–27. - PubMed
  130. de Bruijn HS, Mashayekhi V, Schreurs TJL, van Driel PBAA, Strijkers GJ, van Diest PJ, et al. Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. Theranostics. 2020;10:2436–52. - PubMed
  131. Prantner AM, Yin C, Kamat K, Sharma K, Lowenthal AC, Madrid PB, et al. Molecular imaging of mesothelin-expressing ovarian cancer with a human and mouse cross-reactive nanobody. Mol Pharm. 2018;15:1403–11. - PubMed
  132. Zaman MB, Baral TN, Jakubek ZJ, Zhang J, Wu X, Lai E, et al. Single-domain antibody bioconjugated near-IR quantum dots for targeted cellular imaging of pancreatic cancer. J Nanosci Nanotechnol. 2011;11:3757–63. - PubMed
  133. Van Driel PBAA, Van Der Vorst JR, Verbeek FPR, Oliveira S, Snoeks TJA, Keereweer S, et al. Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. Int J Cancer. 2014;134:2663–73. - PubMed
  134. Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, et al. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. Sci Rep. 2017;7:1–13. - PubMed
  135. Fatehi D, Baral TN, Abulrob A. In vivo imaging of brain cancer using epidermal growth factor single domain antibody bioconjugated to near-infrared quantum dots. J Nanosci Nanotechnol. 2014;14:5355–62. - PubMed
  136. Kijanka MM, van Brussel ASA, van der Wall E, Mali WPTM, van Diest PJ, van Bergen en Henegouwen PMP, et al. Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization. EJNMMI Res. 2016;6:14. - PubMed
  137. Debie P, Vanhoeij M, Poortmans N, Puttemans J, Gillis K, Devoogdt N, et al. Improved debulking of peritoneal tumor implants by near-infrared fluorescent nanobody image guidance in an experimental mouse model. Mol Imaging Biol. 2018;20:361–7. - PubMed
  138. Traenkle B, Rothbauer U. Under the microscope: single-domain antibodies for live-cell imaging and super-resolution microscopy. Front Immunol. 2017;8:1–8. - PubMed
  139. Li T, Bourgeois J, Celli S, Glacial F, Le Sourd A, Mecheri S, et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 2012;26:3969–79. - PubMed
  140. Dong J-X, Lee Y, Kirmiz M, Palacio S, Dumitras C, Moreno CM, et al. A toolbox of nanobodies developed and validated for use as intrabodies and nanoscale immunolabels in mammalian brain neurons. Elife. 2019;8:1–25. - PubMed
  141. Helma J, Schmidthals K, Lux V, Nüske S, Scholz AM, Kräusslich H-G, et al. Direct and dynamic detection of HIV-1 in living cells. PLoS One. 2012;7:e50026. - PubMed
  142. Traenkle B, Emele F, Anton R, Poetz O, Haeussler RS, Maier J, et al. Monitoring interactions and dynamics of endogenous beta-catenin with intracellular nanobodies in living cells. Mol Cell Proteomics. 2015;14:707–23. - PubMed
  143. Buchfellner A, Yurlova L, Nüske S, Scholz AM, Bogner J, Ruf B, et al. A new nanobody-based biosensor to study endogenous PARP1 in vitro and in live human cells. PLoS One. 2016;11:e0151041. - PubMed
  144. van Brussel ASA, Adams A, Oliveira S, Dorresteijn B, El Khattabi M, Vermeulen JF, et al. Hypoxia-targeting fluorescent nanobodies for optical molecular imaging of pre-invasive breast cancer. Mol Imaging Biol. 2016;18:535–44. - PubMed
  145. Sukhanova A, Ramos-Gomes F, Alves F, Chames P, Baty D, Nabiev I. Advanced nanotools for imaging of solid tumors and circulating and disseminated cancer cells. Opt Spectrosc. 2018;125:703–7. - PubMed
  146. Hafian H, Sukhanova A, Turini M, Chames P, Baty D, Pluot M, et al. Multiphoton imaging of tumor biomarkers with conjugates of single-domain antibodies and quantum dots. Nanomedicine. 2014;10:1701–9. - PubMed
  147. Pansieri J, Plissonneau M, Stransky-Heilkron N, Dumoulin M, Heinrich-Balard L, Rivory P, et al. Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting. Nanomedicine. 2017;12:1675–87. - PubMed
  148. Nabuurs RJA, Rutgers KS, Welling MM, Metaxas A, de Backer ME, Rotman M, et al. In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer’s disease. PLoS One. 2012;7:e38284. - PubMed
  149. Gerdes C, Waal N, Offner T, Fornasiero EF, Wender N, Verbarg H, et al. A nanobody-based fluorescent reporter reveals human α-synuclein in the cell cytosol. Nat Commun. 2020;11:2729. - PubMed
  150. Li T, Qi S, Unger M, Hou YN, Deng QW, Liu J, et al. Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep. 2016;6:27055. - PubMed
  151. Schornack S, Fuchs R, Huitema E, Rothbauer U, Lipka V, Kamoun S. Protein mislocalization in plant cells using a GFP-binding chromobody. Plant J. 2009;60:744–54. - PubMed
  152. Hernot S, Unnikrishnan S, Du Z, Shevchenko T, Cosyns B, Broisat A, et al. Nanobody-coupled microbubbles as novel molecular tracer. J Control Release. 2012;158:346–53. - PubMed
  153. Yu Z, Hu M, Li Z, Dan Xu, Zhu L, Guo Y, et al. Anti-G250 nanobody-functionalized nanobubbles targeting renal cell carcinoma cells for ultrasound molecular imaging. Nanotechnology. 2020;31:205101. - PubMed
  154. Zhu M, Li M, Li G, Zhou Z, Liu H, Lei H, et al. Nanobody-based electrochemical immunoassay for Bacillus thuringiensis Cry1Ab toxin by detecting the enzymatic formation of polyaniline. Microchim Acta. 2015;182:2451–9. - PubMed
  155. Lesne J, Chang H-J, De Visch A, Paloni M, Barthe P, Guichou J-F, et al. Structural basis for chemically-induced homodimerization of a single domain antibody. Sci Rep. 2019;9:1840. - PubMed

Publication Types